Report cover image

Global Neuroendocrine Carcinoma Industry Growth and Trends Forecast to 2031

Publisher APO Research, Inc.
Published Oct 20, 2025
Length 101 Pages
SKU # APRC20548848

Description

Summary

According to APO Research, The global Neuroendocrine Carcinoma market was estimated at US$ million in 2025 and is projected to reach a revised size of US$ million by 2031, witnessing a CAGR of xx% during the forecast period 2026-2031.

North American market for Neuroendocrine Carcinoma is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2026 through 2031.

Asia-Pacific market for Neuroendocrine Carcinoma is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2026 through 2031.

Europe market for Neuroendocrine Carcinoma is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2026 through 2031.

The major global companies of Neuroendocrine Carcinoma include Teva, Novartis, Pfizer, Abbvie, Valeant, Mateon, Lexicon, Jubilant and Ipsen, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.

Report Scope

This report aims to provide a comprehensive presentation of the global market for Neuroendocrine Carcinoma, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Neuroendocrine Carcinoma.
The Neuroendocrine Carcinoma market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Neuroendocrine Carcinoma market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided. For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.

Key Companies & Market Share Insights

In this section, the readers will gain an understanding of the key players competing. This report has studied the key growth strategies, such as innovative trends and developments, intensification of product portfolio, mergers and acquisitions, collaborations, new product innovation, and geographical expansion, undertaken by these participants to maintain their presence. Apart from business strategies, the study includes current developments and key financials. The readers will also get access to the data related to global revenue, gross margin by manufacturers for the period 2020-2025. This all-inclusive report will certainly serve the clients to stay updated and make effective decisions in their businesses.

Neuroendocrine Carcinoma Segment by Company

Teva
Novartis
Pfizer
Abbvie
Valeant
Mateon
Lexicon
Jubilant
Ipsen
F.Hoffmann-La Roche
Chiasma
Advanced Accelerator
Neuroendocrine Carcinoma Segment by Type

Somatostatin Analogs
Chemotherapy
Targeted Therapy
Neuroendocrine Carcinoma Segment by Application

Oncology Centres
Clinics
Hospital
Ambulatory Surgery Centres
Neuroendocrine Carcinoma Segment by Region

North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Neuroendocrine Carcinoma market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Neuroendocrine Carcinoma and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Neuroendocrine Carcinoma.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2020-2025, 2026-2031). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 3: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 4: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 5: Detailed analysis of Neuroendocrine Carcinoma companies' competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.
Chapter 7, 8, 9, 10 and 11: North America, Europe, Asia Pacific, South America, Middle East & Africa, revenue by country.
Chapter 12: Concluding Insights of the report

Please Note: Single-User license will be delivered via PDF from the publisher without the rights to print or to edit.

Table of Contents

101 Pages
1 Market Overview
1.1 Product Definition
1.2 Global Market Growth Prospects
1.3 Global Neuroendocrine Carcinoma Market Size Overview by Region 2020 VS 2024 VS 2031
1.4 Global Neuroendocrine Carcinoma Market Size by Region (2020-2031)
1.4.1 Global Neuroendocrine Carcinoma Market Size by Region (2020-2025)
1.4.2 Global Neuroendocrine Carcinoma Market Size by Region (2026-2031)
1.5 Key Regions Neuroendocrine Carcinoma Market Size (2020-2031)
1.5.1 North America Neuroendocrine Carcinoma Market Size Growth Rate (2020-2031)
1.5.2 Europe Neuroendocrine Carcinoma Market Size Growth Rate (2020-2031)
1.5.3 Asia-Pacific Neuroendocrine Carcinoma Market Size Growth Rate (2020-2031)
1.5.4 South America Neuroendocrine Carcinoma Market Size Growth Rate (2020-2031)
1.5.5 Middle East & Africa Neuroendocrine Carcinoma Market Size Growth Rate (2020-2031)
2 Neuroendocrine Carcinoma Market by Type
2.1 Type Introduction
2.1.1 Somatostatin Analogs
2.1.2 Chemotherapy
2.1.3 Targeted Therapy
2.2 Global Neuroendocrine Carcinoma Market Size by Type
2.2.1 Global Neuroendocrine Carcinoma Market Size Overview by Type (2020-2031)
2.2.2 Global Neuroendocrine Carcinoma Historic Market Size Review by Type (2020-2025)
2.2.3 Global Neuroendocrine Carcinoma Market Size Forecasted by Type (2026-2031)
2.3 Global Neuroendocrine Carcinoma Market Size by Regions
2.3.1 North America Neuroendocrine Carcinoma Market Size Breakdown by Type (2020-2025)
2.3.2 Europe Neuroendocrine Carcinoma Market Size Breakdown by Type (2020-2025)
2.3.3 Asia-Pacific Neuroendocrine Carcinoma Market Size Breakdown by Type (2020-2025)
2.3.4 South America Neuroendocrine Carcinoma Market Size Breakdown by Type (2020-2025)
2.3.5 Middle East and Africa Neuroendocrine Carcinoma Market Size Breakdown by Type (2020-2025)
3 Neuroendocrine Carcinoma Market by Application
3.1 Type Introduction
3.1.1 Oncology Centres
3.1.2 Clinics
3.1.3 Hospital
3.1.4 Ambulatory Surgery Centres
3.2 Global Neuroendocrine Carcinoma Market Size by Application
3.2.1 Global Neuroendocrine Carcinoma Market Size Overview by Application (2020-2031)
3.2.2 Global Neuroendocrine Carcinoma Historic Market Size Review by Application (2020-2025)
3.2.3 Global Neuroendocrine Carcinoma Market Size Forecasted by Application (2026-2031)
3.3 Global Neuroendocrine Carcinoma Market Size by Regions
3.3.1 North America Neuroendocrine Carcinoma Market Size Breakdown by Application (2020-2025)
3.3.2 Europe Neuroendocrine Carcinoma Market Size Breakdown by Application (2020-2025)
3.3.3 Asia-Pacific Neuroendocrine Carcinoma Market Size Breakdown by Application (2020-2025)
3.3.4 South America Neuroendocrine Carcinoma Market Size Breakdown by Application (2020-2025)
3.3.5 Middle East and Africa Neuroendocrine Carcinoma Market Size Breakdown by Application (2020-2025)
4 Global Market Dynamics
4.1 Neuroendocrine Carcinoma Industry Trends
4.2 Neuroendocrine Carcinoma Industry Drivers
4.3 Neuroendocrine Carcinoma Industry Opportunities and Challenges
4.4 Neuroendocrine Carcinoma Industry Restraints
5 Competitive Insights by Company
5.1 Global Top Players by Neuroendocrine Carcinoma Revenue (2020-2025)
5.2 Global Neuroendocrine Carcinoma Industry Company Ranking, 2023 VS 2024 VS 2025
5.3 Global Neuroendocrine Carcinoma Key Company Headquarters & Area Served
5.4 Global Neuroendocrine Carcinoma Company, Product Type & Application
5.5 Global Neuroendocrine Carcinoma Company Commercialization Time
5.6 Market Competitive Analysis
5.6.1 Global Neuroendocrine Carcinoma Market CR5 and HHI
5.6.2 Global Top 5 and 10 Neuroendocrine Carcinoma Players Market Share by Revenue in 2024
5.6.3 2024 Neuroendocrine Carcinoma Tier 1, Tier 2, and Tier 3
6 Company Profiles
6.1 Teva
6.1.1 Teva Comapny Information
6.1.2 Teva Business Overview
6.1.3 Teva Neuroendocrine Carcinoma Revenue, Global Share and Gross Margin (2020-2025)
6.1.4 Teva Neuroendocrine Carcinoma Product Portfolio
6.1.5 Teva Recent Developments
6.2 Novartis
6.2.1 Novartis Comapny Information
6.2.2 Novartis Business Overview
6.2.3 Novartis Neuroendocrine Carcinoma Revenue, Global Share and Gross Margin (2020-2025)
6.2.4 Novartis Neuroendocrine Carcinoma Product Portfolio
6.2.5 Novartis Recent Developments
6.3 Pfizer
6.3.1 Pfizer Comapny Information
6.3.2 Pfizer Business Overview
6.3.3 Pfizer Neuroendocrine Carcinoma Revenue, Global Share and Gross Margin (2020-2025)
6.3.4 Pfizer Neuroendocrine Carcinoma Product Portfolio
6.3.5 Pfizer Recent Developments
6.4 Abbvie
6.4.1 Abbvie Comapny Information
6.4.2 Abbvie Business Overview
6.4.3 Abbvie Neuroendocrine Carcinoma Revenue, Global Share and Gross Margin (2020-2025)
6.4.4 Abbvie Neuroendocrine Carcinoma Product Portfolio
6.4.5 Abbvie Recent Developments
6.5 Valeant
6.5.1 Valeant Comapny Information
6.5.2 Valeant Business Overview
6.5.3 Valeant Neuroendocrine Carcinoma Revenue, Global Share and Gross Margin (2020-2025)
6.5.4 Valeant Neuroendocrine Carcinoma Product Portfolio
6.5.5 Valeant Recent Developments
6.6 Mateon
6.6.1 Mateon Comapny Information
6.6.2 Mateon Business Overview
6.6.3 Mateon Neuroendocrine Carcinoma Revenue, Global Share and Gross Margin (2020-2025)
6.6.4 Mateon Neuroendocrine Carcinoma Product Portfolio
6.6.5 Mateon Recent Developments
6.7 Lexicon
6.7.1 Lexicon Comapny Information
6.7.2 Lexicon Business Overview
6.7.3 Lexicon Neuroendocrine Carcinoma Revenue, Global Share and Gross Margin (2020-2025)
6.7.4 Lexicon Neuroendocrine Carcinoma Product Portfolio
6.7.5 Lexicon Recent Developments
6.8 Jubilant
6.8.1 Jubilant Comapny Information
6.8.2 Jubilant Business Overview
6.8.3 Jubilant Neuroendocrine Carcinoma Revenue, Global Share and Gross Margin (2020-2025)
6.8.4 Jubilant Neuroendocrine Carcinoma Product Portfolio
6.8.5 Jubilant Recent Developments
6.9 Ipsen
6.9.1 Ipsen Comapny Information
6.9.2 Ipsen Business Overview
6.9.3 Ipsen Neuroendocrine Carcinoma Revenue, Global Share and Gross Margin (2020-2025)
6.9.4 Ipsen Neuroendocrine Carcinoma Product Portfolio
6.9.5 Ipsen Recent Developments
6.10 F.Hoffmann-La Roche
6.10.1 F.Hoffmann-La Roche Comapny Information
6.10.2 F.Hoffmann-La Roche Business Overview
6.10.3 F.Hoffmann-La Roche Neuroendocrine Carcinoma Revenue, Global Share and Gross Margin (2020-2025)
6.10.4 F.Hoffmann-La Roche Neuroendocrine Carcinoma Product Portfolio
6.10.5 F.Hoffmann-La Roche Recent Developments
6.11 Chiasma
6.11.1 Chiasma Comapny Information
6.11.2 Chiasma Business Overview
6.11.3 Chiasma Neuroendocrine Carcinoma Revenue, Global Share and Gross Margin (2020-2025)
6.11.4 Chiasma Neuroendocrine Carcinoma Product Portfolio
6.11.5 Chiasma Recent Developments
6.12 Advanced Accelerator
6.12.1 Advanced Accelerator Comapny Information
6.12.2 Advanced Accelerator Business Overview
6.12.3 Advanced Accelerator Neuroendocrine Carcinoma Revenue, Global Share and Gross Margin (2020-2025)
6.12.4 Advanced Accelerator Neuroendocrine Carcinoma Product Portfolio
6.12.5 Advanced Accelerator Recent Developments
7 North America
7.1 North America Neuroendocrine Carcinoma Market Size Growth Rate (CAGR) by Country: 2020 VS 2024 VS 2031
7.2 North America Neuroendocrine Carcinoma Market Size by Country (2020-2025)
7.3 North America Neuroendocrine Carcinoma Market Size Forecast by Country (2026-2031)
8 Europe
8.1 Europe Neuroendocrine Carcinoma Market Size Growth Rate (CAGR) by Country: 2020 VS 2024 VS 2031
8.2 Europe Neuroendocrine Carcinoma Market Size by Country (2020-2025)
8.3 Europe Neuroendocrine Carcinoma Market Size Forecast by Country (2026-2031)
9 Asia-Pacific
9.1 Asia-Pacific Neuroendocrine Carcinoma Market Size Growth Rate (CAGR) by Country: 2020 VS 2024 VS 2031
9.2 Asia-Pacific Neuroendocrine Carcinoma Market Size by Country (2020-2025)
9.3 Asia-Pacific Neuroendocrine Carcinoma Market Size Forecast by Country (2026-2031)
10 South America
10.1 South America Neuroendocrine Carcinoma Market Size Growth Rate (CAGR) by Country: 2020 VS 2024 VS 2031
10.2 South America Neuroendocrine Carcinoma Market Size by Country (2020-2025)
10.3 South America Neuroendocrine Carcinoma Market Size Forecast by Country (2026-2031)
11 Middle East & Africa
11.1 Middle East & Africa Neuroendocrine Carcinoma Market Size Growth Rate (CAGR) by Country: 2020 VS 2024 VS 2031
11.2 Middle East & Africa Neuroendocrine Carcinoma Market Size by Country (2020-2025)
11.3 Middle East & Africa Neuroendocrine Carcinoma Market Size Forecast by Country (2026-2031)
12 Concluding Insights
13 Appendix
13.1 Reasons for Doing This Study
13.2 Research Methodology
13.3 Research Process
13.4 Authors List of This Report
13.5 Data Source
13.5.1 Secondary Sources
13.5.2 Primary Sources
How Do Licenses Work?
Request A Sample
Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.